|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Substance Dependence - Part II: Alcohol
Datamonitor, Dec 2007, Pages: 93
The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m across the seven major markets by 2016. The alcohol dependence market requires a paradigm shift away from the public perception that it is a behavioral disorder towards being regarded as a treatable medical condition.
Scope
- Analysis of epidemiology, unmet needs and clinical trial design in alcohol dependence with insight from key opinion leaders
- Overview of the current alcohol dependence market.
- Analysis of patient potential, marketing factors, commercial attractiveness and clinical attractiveness of key late-stage pipeline drugs.
- Indication-specific forecasts of key drug key late-stage pipeline drugs revenues to 2016.
Highlights of this title
The current alcohol dependence pipeline is small in comparison to other central nervous system markets. Opioid antagonists are the most prevalent drug class in late-stage development and include two reformulations of naltrexone. Datamonitor therefore believes the current alcohol dependence pipeline to be weak and lacking in innovation.
The efficacy of currently marketed pharmaceutical products is limited, thereby leaving market opportunity for new therapies. Furthermore, in view of the poor medication compliance rate in alcohol dependent patients, pipeline drugs that possess the potential to improve patient compliance can expect to receive a strong uptake.
Companies developing naltrexone depot drugs will experience difficulty distinguishing their products from Vivitrol (naltrexone once-monthly controlled-release, Alkermes/Cephalon) unless they price their drugs competitively and/or incorporate an injection device that produces less pain and fewer injection site reactions.
Key reasons to purchase this title
- Understand unmet needs and opportunities in this market based on the comments of interviewed key opinion leaders.
- Benchmark key late-stage alcohol dependence compounds against the current market leader.
- Assess the seven major market total sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential.
Customers who bought this item also bought
World Market for Addiction Disorders, 2009–2016, The Future Therapies for Substance Dependence and Impulse Control
Pipeline Insight: Substance Dependence - Part I: Nicotine
Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential
Nicotine Dependence Market Forecast
Pipeline Insight: HIV - Novel NNRTIs address crucial unmet need
Alcohol/Substance Abuse & Dependency - Evaluation and Management 2nd Edition, 2009 Update
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
Pipeline Insight: Depression - Novel Drugs to Grow Third-line Market
Pipeline and Commercial Insight: Hepatitis C - High Unmet Need Drives Rapid Innovation
Pipeline Insight: Heart failure Weak pipeline dominated by new indications and add-on diuretics
Pipeline Insight: Acute Stroke: Commercial Risk Offsets High Unmet Need
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit
|
|
|
|
